ANP presenting now, page-58

50c now, would be a market cap of just over$ US 219 million (undiluted).

Thats pretty cheap for a drug potentially just 1 trial away from approval. I would think if they thought they could they might.

But listen to the story that ANP is now telling. They are confident of success. They are positioning the right people in the right positions. The have said they are willing to go it alone. So it seems pretty like the ANP BOD have confidence and see value in the company.

Any take over now would be multiples more than what was required this time last year.

Any take over offer after EMA and FDA trial approval will be higher again.

Any take over once a self funded trial is well underway will be multiples away from where we are now.

A take over towards the end of the trial, if results are proving to be similiar to the last trial, will be eye watering as the company is on the verge of a protected revenue stream.

Its almost like that chart pattern where share prices are squeesed prior to a breakout.

The potential of drug approval after the next trial, with EMA and FDA ODDs, and the FDA RPDV all combine to create potential value.

As Sam says, for now we wait. But what a great period of time to be an ANP share holder. And what great hope for the boys that suffer from this disease.